Hacker News new | past | comments | ask | show | jobs | submit login

You should re-read the article.

>Last year, Gilead entered into an agreement with India that would allow Indian pharmaceutical manufacturers to produce generic versions of Harvoni and Sovaldi and sell them in 101 developing countries at "a significantly reduced flat price."

>If you buy Hepcinat from India, Gilead still makes a profit as part of its licensing arrangement, but it doesn't make the unholy profits the U.S. government allows it to get away with.




Join us for AI Startup School this June 16-17 in San Francisco!

Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: